TY - JOUR
T1 - Transarterial radioembolization with Yttrium-90 for regional management of hepatocellular cancer
T2 - The early results of a nontransplant center
AU - Holt, Alicia
AU - Wagman, Lawrence D.
AU - Senthil, Maheswari
AU - McKenzie, Shaun
AU - Marx, Howard
AU - Chen, Yi Jen
AU - Vora, Nayana
AU - Kim, Joseph
PY - 2010/10
Y1 - 2010/10
N2 - Selective arterial radioembolization with Yttrium-90 (Y-90) microspheres has shown promise for regional management of hepatocellular cancer (HCC). Our objective was to report our early experience with this treatment modality from a nontransplant center. Treatment of patients with HCC was discussed in a multidisciplinary tumor board. Patients with unresectable disease resulting from high lesion number, ill location of the tumor, poor hepatic reserve, or medical comorbidities were offered Y-90 treatment. Liver treatment was either lobar or tumor-targeted. Response to therapy was assessed by CT scan obtained within 3 months using Response Evaluation Criteria in Solid Tumors criteria. During 2007 to 2009, 40 Y-90 radioembolizations were performed in 20 patients with age that ranged from 16 to 87 years; four patients were 80 years old or older. After the first therapy, CT assessment of the treated area showed stable disease (n = 15), partial response (n = 3), and progression (n = 2). Of the two patients who progressed, one was retreated with a subsequent complete response. The other patient died of progressive disease. The most common side effects were mild fatigue, anorexia, and nausea. In summary, our nontransplant center experience shows that Y-90 radioembolization is a well-tolerated treatment in select patients with unresectable HCC with an associated high rate of local tumor control.
AB - Selective arterial radioembolization with Yttrium-90 (Y-90) microspheres has shown promise for regional management of hepatocellular cancer (HCC). Our objective was to report our early experience with this treatment modality from a nontransplant center. Treatment of patients with HCC was discussed in a multidisciplinary tumor board. Patients with unresectable disease resulting from high lesion number, ill location of the tumor, poor hepatic reserve, or medical comorbidities were offered Y-90 treatment. Liver treatment was either lobar or tumor-targeted. Response to therapy was assessed by CT scan obtained within 3 months using Response Evaluation Criteria in Solid Tumors criteria. During 2007 to 2009, 40 Y-90 radioembolizations were performed in 20 patients with age that ranged from 16 to 87 years; four patients were 80 years old or older. After the first therapy, CT assessment of the treated area showed stable disease (n = 15), partial response (n = 3), and progression (n = 2). Of the two patients who progressed, one was retreated with a subsequent complete response. The other patient died of progressive disease. The most common side effects were mild fatigue, anorexia, and nausea. In summary, our nontransplant center experience shows that Y-90 radioembolization is a well-tolerated treatment in select patients with unresectable HCC with an associated high rate of local tumor control.
UR - http://www.scopus.com/inward/record.url?scp=78651364201&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78651364201&partnerID=8YFLogxK
M3 - Article
C2 - 21105614
AN - SCOPUS:78651364201
SN - 0003-1348
VL - 76
SP - 1079
EP - 1083
JO - American Surgeon
JF - American Surgeon
IS - 10
ER -